

## FONT 2 – Novel Therapies in Resistant Focal Segmental Glomerulosclerosis

Visit us online at [www.fonttrial.org](http://www.fonttrial.org)

**Status:** Recruiting

**Study Summary:** This is a Phase II randomized clinical trial for people with Focal Segmental Glomerulosclerosis (FSGS) who are unresponsive to other drugs. The study will test if two new drugs – adalimumab (Humira®) or galactose --can lower urine protein levels and preserve kidney function. All patients will receive lisinopril (Prinivil®), losartan (Cozaar®), and atorvastatin (Lipitor®).

**About this Study:** 126 patients – 42 in each arm -- with FSGS will take part in FONT 2. There are 7 visits in the first 6 months of this study. There are 20 centers in the United States and Canada that are part of this study. See the list below of these centers

**To be able to participate in the FONT 2 study, people must:**

- Not responsive steroids or not able to take them
- Not responsive to at least one other medicine for FSGS
- Ages 1 - 65 years

**Excusion Criteria**

- Organ transplant
- Kidney failure
- Diabetes

**How to be part of this study:** Call Toll Free: 855-4-FONT II (855-496-6244) or email [font2@umich.edu](mailto:font2@umich.edu).

**Study Centers in the United States and Canada are:**

Columbia University Medical Center	Children's Hospital Boston	Children's Mercy Hospital
Cincinnati Children's Hospital	Cohen Children's Hospital	Doernbecher Children's Hospital
Emory University	Levine Children's Hospital	Mayo Clinic
University of Michigan	Medical University of South Carolina	University of Miami
Nationwide Children's Hospital	New York University	SSM Cardinal Glennon Children's Medical Center
Texas Tech University	University of Alberta	University of Kansas